Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of MEDI0618 in Healthy Volunteers
NCT04198558Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Nov 2019
- Primary completion
- Feb 2022
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of MEDI0618 in chronic pain (9 arms), sponsored by AstraZeneca. Primary endpoints: Incidence of Treatment-Emergent Adverse Events up to 85 days, Incidence of Treatment-Emergent Serious Adverse Events up to 85 days and 10 more. Started Nov 2019; status: completed.
02
Drugs
MEDI0618
03
Conditions
chronic pain
Beyond the preview
Go deeper on NCT04198558.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04198558.